Researchers tested the MET inhibitor capmatinib in patients with non–small-cell lung cancer and a MET exon 14 skipping mutation.
Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.
The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial.
Researchers tested the addition of a pemetrexed-carboplatin chemotherapy regimen to gefitinib for patients with EGFR-mutant advanced non–small-cell lung cancer.
A retrospective study finds that use of checkpoint inhibitors is associated with similar survival outcomes among patients with advanced non–small-cell lung cancer, regardless of a history of autoimmune disorders.
The RELAY trial compared the combination of ramucirumab plus erlotinib vs erlotinib alone in patients with metastatic non–small-cell lung cancer.
It may be possible to double the number of patients eligible for clinical trials for advanced lung cancer by expanding trial eligibility criteria based on new technologies and advances in supportive care.
The study evaluated the efficacy and tolerability of adjuvant treatment with pemetrexed/cisplatin vs vinorelbine/cisplatin in patients with non-squamous NSCLC.
Researchers compared the percentage of non-viable tumor and tissue resident memory tumor infiltrating lymphocytes for nivolumab plus ipilimumab vs nivolumab alone.
Results from an interim efficacy analysis of a large, multicenter clinical trial focusing on a programmed death ligand 1 inhibitor were presented at ASCO 2019.